Atheroma Reduction With Chloroquine in Patients With the Metabolic Syndrome (ARCH-MS)
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
Metabolic syndrome consists of a group of co-occuring conditions that increase an
individual's risk of developing heart disease, stroke, and diabetes. The purpose of this
study is to evaluate the long-term effectiveness of chloroquine, a protein-activation
medication, at reducing the progression of atherosclerosis in patients with the metabolic
syndrome.
Sub-study: Vascular endothelial growth factor(VEGF)and Cardiometabolic Risk, The purpose is
to determine if the association of VEGF with atherosclerosis indicates that it should be a
marker of the disorder.
Phase:
N/A
Details
Lead Sponsor:
Washington University School of Medicine
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI) Singulex